Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, utilizing its PRISM platform to develop treatments for disorders like Duchenne muscular dystrophy and Huntington’s disease. Founded in 2015, it employs 266 people and is advancing RNA-targeting modalities such as editing and interference.
Paul Bolno sold 169,025 shares of WVE on 7 March at $9.57 per share, worth a total of $1.6M. They now own 338,351 WVE shares, or a 33% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
